Meyka Pro banner
Geron Corporation

Geron Corporation Fundamental Analysis (NASDAQ: GERN)

GERN●NASDAQ
HealthcareBiotechnology
$0.94
$0.21(18.44%)
U.S. Market is Open · 15:37

Geron Corporation Fundamental Analysis (NASDAQ: GERN)

Geron Corporation (NASDAQ: GERN) shows weak financial fundamentals with a PE ratio of -9.65, profit margin of -34.17%, and ROE of -30.31%. The company generates $0.2B in annual revenue with weak year-over-year growth of 1.39%.

Key Strengths

Cash Position46.32%
PEG Ratio-0.44
Current Ratio6.92

Areas of Concern

ROE-30.31%
Operating Margin-18.29%
We analyze GERN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -11.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-11.8/100

We analyze GERN's fundamental strength across five key dimensions:

Efficiency Score

Weak

GERN struggles to generate sufficient returns from assets.

ROA > 10%
-13.47%

Valuation Score

Excellent

GERN trades at attractive valuation levels.

PE < 25
-9.65
PEG Ratio < 2
-0.44

Growth Score

Moderate

GERN shows steady but slowing expansion.

Revenue Growth > 5%
1.39%
EPS Growth > 10%
51.85%

Financial Health Score

Excellent

GERN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.56
Current Ratio > 1
6.92

Profitability Score

Weak

GERN struggles to sustain strong margins.

ROE > 15%
-3031.29%
Net Margin ≥ 15%
-34.17%
Positive Free Cash Flow
No

Key Financial Metrics

Is GERN Expensive or Cheap?

P/E Ratio

GERN trades at -9.65 times earnings. This suggests potential undervaluation.

-9.65

PEG Ratio

When adjusting for growth, GERN's PEG of -0.44 indicates potential undervaluation.

-0.44

Price to Book

The market values Geron Corporation at 2.95 times its book value. This may indicate undervaluation.

2.95

EV/EBITDA

Enterprise value stands at -13.51 times EBITDA. This is generally considered low.

-13.51

How Well Does GERN Make Money?

Net Profit Margin

For every $100 in sales, Geron Corporation keeps $-34.17 as profit after all expenses.

-34.17%

Operating Margin

Core operations generate -18.29 in profit for every $100 in revenue, before interest and taxes.

-18.29%

ROE

Management delivers $-30.31 in profit for every $100 of shareholder equity.

-30.31%

ROA

Geron Corporation generates $-13.47 in profit for every $100 in assets, demonstrating efficient asset deployment.

-13.47%

Following the Money - Real Cash Generation

Operating Cash Flow

Geron Corporation generates limited operating cash flow of $-109.56M, signaling weaker underlying cash strength.

$-109.56M

Free Cash Flow

Geron Corporation generates weak or negative free cash flow of $-109.96M, restricting financial flexibility.

$-109.96M

FCF Per Share

Each share generates $-0.17 in free cash annually.

$-0.17

FCF Yield

GERN converts -18.42% of its market value into free cash.

-18.42%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-9.65

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.44

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.95

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.02

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.56

vs 25 benchmark

Current Ratio

Current assets to current liabilities

6.92

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.30

vs 25 benchmark

ROA

Return on assets percentage

-0.13

vs 25 benchmark

ROCE

Return on capital employed

-0.08

vs 25 benchmark

How GERN Stacks Against Its Sector Peers

MetricGERN ValueSector AveragePerformance
P/E Ratio-9.6531.78 Better (Cheaper)
ROE-30.31%543.00% Weak
Net Margin-34.17%5160.00% Weak
Debt/Equity0.560.07 Weak (High Leverage)
Current Ratio6.925.73 Strong Liquidity
ROA-13.47%-182.00% (disorted) Weak

GERN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Geron Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

29494.86%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

53.81%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

32.16%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ